Welcome to the U.S. Hereditary Angioedema Association's website. We are a non-profit patient advocacy organization dedicated to providing wide-ranging services to HAE patients and pioneering new HAE research. Our services include clinical trial placement, physician referrals, education, and individualized patient case management.
Comprehensive Angioedema
Typology and Description
HAE Clinical Trials Offer Hope
for Better Therapies
Bibliography of HAE Articles
(Jan 1, 2000 - Jun 1, 2009)
Three products have recently been FDA-approved! The Cinryze ™ brand of C1-inhibitor concentrate was approved for preventing HAE attacks. The Berinert ® brand of C1-inhibitor concentrate was approved for acute facial and abdominal attacks. Kalbitor®, the new product from Dyax Corp., has now been approved to treat acute HAE attacks in patients 16 years of age and older
Please contact the HAEA's Patient Services group for more information.
Online Communities
Register to be a member of our message forum or subscribe to our patient email support group
HAE Guide
Everything you need to know about HAE diagnosis and treatment
Angioedema Table
Find out the difference between the different types of Angioedema
Clinical Trials
Bring much-needed HAE treatment to the US. Sign up to participate in the clinical trials
New Treatment Options
Learn about the ongoing clinical trials which will revolutionize the way HAE attacks are treated.
Physician Referral
Find a physician near you.
HAE Patient Identification Card
click here for details on how to get yours!
February 2010 Read our Winter 2009 Newsletter
KALBITOR® (ecallantide) Now Commercially Available
December 2, 2009
Dyax Announces FDA Approval of KALBITOR® (ecallantide) for the Treatment of Acute Attacks of Hereditary Angioedema in Patients 16 Years of Age and Older
Sept. 2009 Read our Fall 2009 Newsletter
August 2009
Sign up to participate in our Scientific Registry, and help find a cure for HAE
HAEA.org wins the 2009 AAAAI Distinguished Layperson Award.
March 2009
Watch news coverage on how Cinryze is transforming an HAE patient's life.
DX-88 (ecallantide) Demonstrated Relief of Symptoms in Hereditary Angioedema Acute Attacks in All Attack Locations
October 12, 2009
CSL Behring Announces FDA Approval of Berinert(R), First and Only Therapy Approved for the Treatment of Acute Abdominal and Facial Attacks of Hereditary Angioedema in U.S.
October 9, 2009
FDA Approves Berinert to Treat Abdominal Attacks, Facial Swelling Associated With Hereditary Angioedema
The US HAEA is proud to be a Partner in Rare Disease Day, Feb. 28, 2010!
